

CORRECTED VERSION

(19) World Intellectual Property Organization International Bureau



(43) International Publication Date
17 February 2005 (17.02.2005)

PCT

(10) International Publication Number
WO 2005/014585 A1

(51) International Patent Classification⁷: C07D 405/04, 405/06, 405/14, 413/14, 417/14, A61K 31/395

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(21) International Application Number:
PCT/CA2004/001466

(22) International Filing Date: 6 August 2004 (06.08.2004)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
60/493,336 8 August 2003 (08.08.2003) US

(71) Applicant (for all designated States except US): ULYSSES PHARMACEUTICAL PRODUCTS INC. [CA/CA]; 238 Ch. d'Orford-sur-le Lac, Eastman, Quebec J0E 1P0 (CA).

(72) Inventors; and
(75) Inventors/Applicants (for US only): CHAMBERLAND, Suzanne [CA/CA]; 238 Ch. d'Orford-sr-le-Lac, Eastman, Quebec J0E 1P0 (CA). MALOUIN, Francois [CA/CA]; 238 Ch. d'Orford-sur-le-Lac, Eastman, Quebec J0E 1P0 (CA).

(74) Agents: SCHWARTZ, David, E. et al.; Smart & Biggar, Suite 3300, 1000 de La Gauchetiere Street West, Montreal, Quebec H3B 4W5 (CA).

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:


— with international search report

(48) Date of publication of this corrected version:
9 September 2005

(15) Information about Correction:
see PCT Gazette No. 36/2005 of 9 September 2005, Section II

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: HALOGENATED QUINAZOLINYL NITROFURANS AS ANTIBACTERIAL AGENTS



proviso that at least one of R₃ and R₄ is halogen; and pharmaceutically acceptable formulations of said compounds which exhibit antibiotic activity against a wide spectrum of microorganisms including organisms which are resistant to multiple antibiotic families and are useful as antibacterial agents for treatment or prophylaxis of bacterial infections, or their use as antiseptics, agents for sterilization or disinfection.

(57) Abstract: The present invention includes novel compounds of the formula (I) wherein X is absent or trans or cis CHCH, R₁ is (C₁-C₁₀) alkyl unsubstituted or substituted by one to three hydroxy, (C₁-C₁₀) alkenyl unsubstituted or substituted by one to three hydroxy, (C₁-C₁₀) alkynyl unsubstituted or substituted by one to three hydroxy, or aryl unsubstituted or substituted by one to three hydroxy; R₂ is hydrogen, alkyl or aryl; R₃ and R₄ are, independently of each other, H, halogen, or a solubilizing group, with the

WO 2005/014585 A1

(19) World Intellectual Property Organization International Bureau



(43) International Publication Date
17 February 2005 (17.02.2005)

PCT

(10) International Publication Number
WO 2005/014585 A1

(51) International Patent Classification⁷: **C07D 405/04**, 405/06, 405/14, 413/14, 417/14, A61K 31/395

(21) International Application Number:
PCT/CA2004/001466

(22) International Filing Date: 6 August 2004 (06.08.2004)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
60/493,336 8 August 2003 (08.08.2003) US

(71) Applicant (for all designated States except US): **ULYSSES PHARMACEUTICALS PRODUCTS INC.** [CA/CA]; 238 Ch. d'Orford-sur-le Lac, Eastman, Quebec J0E 1P0 (CA).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **CHAMBERLAND, Suzanne** [CA/CA]; 238 Ch. d'Orford-sr-le-Lac, Eastman, Quebec J0E 1P0 (CA). **MALOUIN, Francois** [CA/CA]; 238 Ch. d'Orford-sur-le Lac, Eastman, Quebec J0E 1P0 (CA).

(74) Agents: **SCHWARTZ, David, E. et al.**; Smart & Biggar, Suite 3300, 1000 de La Gauchetiere Street West, Montreal, Quebec H3B 4W5 (CA).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.


(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

- with international search report
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: HALOGENATED QUINAZOLINYL NITROFURANS AS ANTIBACTERIAL AGENTS



a solubilizing group, with the proviso that at least one of R₃ and R₄ is halogen; and pharmaceutically acceptable salts thereof. The invention also includes pharmaceutically acceptable formulations of said compounds which exhibit antibiotic activity against a wide spectrum of microorganisms including organisms which are resistant to multiple antibiotic families and are useful as antibacterial agents for treatment or prophylaxis of bacterial infections, or their use as antiseptics, agents for sterilization or disinfection.

(57) Abstract: The present invention includes novel compounds of the formula (I) wherein X is absent or trans or cis CH₂CH, R₁ is (C₁-C₁₀) alkyl unsubstituted or substituted by one to three hydroxy, (C₁-C₁₀) alkenyl unsubstituted or substituted by one to three hydroxy, (C₁-C₁₀) alkynyl unsubstituted or substituted by one to three hydroxy, or aryl unsubstituted or substituted by one to three hydroxy; R₂ is hydrogen, alkyl or aryl; R₃ and R₄ are, independently of each other, H, halogen, or